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Abstract:
Antibiotic resistance is one of the greatest public health challenges of our time. There is
an urgent need to discover new antibiotics to combat these drug resistant infections. The MEP
pathway is essential to most bacteria and not found in humans which makes it a desirable target
for novel antibiotic discovery. The IspF enzyme is the fifth enzyme in the MEP pathway.
Screening of a library of approximately 3000 compounds by the Hagen group identified several
sulfa drugs that were ligands for the IspF enzyme. The purpose of this research was to synthesize
sulfonamide derivative compounds for IspF inhibition. In this project, the target sulfonamide
compounds have fluorescent properties. A fluorescent probe will allow the development of a
quantitative ligand binding assays for the IspF enzyme. In this work, a fragment merging
technique was utilized to design target molecules that should bind to the IspF enzyme. The target
molecules were successfully synthesized; however, the purity was below acceptable guidelines.
Several methods were attempted to purify the compounds.
Introduction:
Many different kinds of pathogenic microbes are evolving and becoming resistant to
current medications.1 This is a huge concern to our society as many of these microbes, such as
malaria and HIV, has shown to be extremely deadly to our species. Without medications to
combat these pathogens, the human species will go back to the dark ages with minimal medical
treatment, erasing all of our medical advancements causing them to be obsolete.1 Therefore,
resistant microbes can cause an epidemic in the medical field costing trillions of dollars.1
Currently, there are many antibiotics that are no longer proving to be effective, as bacteria grow
resistant to the current antibiotics.1 Presently in the United States of America, over 2 million
people are infected with drug resistant bacteria each year. Of those infected, over 23,000 people
will die.8 Without exploring more ways to eliminate these microbes, humans will potentially lose
the fight against disease which will dramatically increase mortality worldwide. It is projected
that by the year 2050 the leading cause of death worldwide will be from drug resistant bacterial
infections and that over 10 million people will die each year, far surpassing deaths from cancer
and heart disease.1
Thus, a possible solution to this problem is synthesizing sulfonamide compounds that can
inhibit IspF in the MEP, methylerythritol phosphate, pathway. The reason to attack the IspF
enzyme in the MEP pathway is because this pathway is only found in bacterial microbes, plants,
and protozoa which means that it will not have any harmful effects on humans.2 Another reason
to attack the IspF enzyme is because there are studies that support sulfonamides having
inhibiting characteristics specifically for this enzyme.3,4 The MEP pathway is a good potential
target for pharmaceuticals because it is essential for microbial growth, and none of the enzymes
in the MEP pathway are present in mammalian cells.4 Sulfonamides are essentially easy to
synthesis in laboratories, and there are many different types of sulfonamides that can be
synthesized, allowing for a wide range of molecules to utilize.5 IspF is also one of three enzymes
that can be targets for pharmaceuticals.6 It also has been shown to be a commercially viable
antibiotic agent.4 Therefore, sulfonamide’s molecular characteristics can bind to IspF to inhibit it
which can be employed by fluorescent enzyme assays, where the sulfonamides being synthesized

have fluorescent abilities which can be indictive in its binding affinity to IspF. By using these
assays, it produces KD values based on the fluorescence of the molecules.7 This creates an
effective and quick way in producing results to test this claim.

Figure 1: The methylerythritol phosphate, MEP, pathway in human pathogens. This pathway is
used in bacteria, plants, and apicomplexan protozoa as a way to produce essential isoprenoid
precursors.2 Specifically, the fifth step in this pathway produces 2C-methyl-D-erythritol 2,4cyclopyrophosphate, MEcPP, from the IspF enzyme which is the target for inhibition.

Figure 2: The IspF enzyme which is a homotrimer, where subunits are the colored blue, orange
and green ribbons. Zn2+ cations are displayed as grey spheres, and sulfate and CDP are displayed
as sticks.
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Figure 3: A) X-ray structure of sulfapyridine bound to IspF enzyme. B) X-ray structure of dansylamide.
The Zn2+ cations are displayed as grey spheres, and ligands are displayed as sticks. C) Strategy to merge
the pyridyl moiety of sulfapyridine with dansylamide to create target molecule.

Methods/Design:
As shown in figure 3, the strategy used to design the target molecules was to merge the
structures of the IspF ligands, dansylamide and sulfapyridine. Fragment merging is a well known
technique that is used to create new ligands that have increased potency for an enzyme target.
This merging strategy as applied to the IspF enzyme should result in a compound that has better
potency than either ligand individually. As shown in figure 3 that pyridiyl group could be
merged with the dansylamide to result in a new compound.

Figure 4: The outlined reaction for the synthesis of 5-(dimethylamino)-N-(pyridine-2yl)naphthalene-1-sulfonamide.

Figure 5: The reaction for the synthesis of 5-(dimethylamino)-N-(pyridine-4-yl)naphthalene-1sulfonamide.
This chemical reaction was used for all the syntheses where the only factor that changed
was the aminopyridine group. The aminopyridine and dansyl chloride starting masses were
calculated using their molecular weights and mole to mole ratios. Then, each starting reagent was
weighed out according to its mass amount needed using a 1 millimole ratio scale between the
two reagents. The reaction was conducted under nitrogen atmosphere at room temperature,
where it stirred for 2-4 days.7 Dichloromethane was used along with triethylamine to dissolve the
reagents on a needed basis.7 After 2-4 days, TLC’s were conducted on all of the crude products
and starting reagents to conclude if a new spot was present which indicants the possibility of the
final product in the solution. The solvent was evaporated off by either the rotary evaporator,
vacuum oven or pump, or on its own.7 The crude product underwent either recrystallization with
methanol or Biotage chromatography.7 Proton NMR’s at 300 MHz were done on all crude
products as well as final products. The purification steps varied depending on impurities present
in the product.

Results:

Figure 6: Proton NMR at 300 MHz of the final product of 5-(dimethylamino)-N-(pyridine-2yl)naphthalene-1-sulfonamide which is present based on the placement of hydrogens on the
molecule displayed on the spectra.
However, there are still impurities showing at 3.1 of the triethylamine hydrochloride and
a couple near 6 and 6.7. Some solvent lines are present in the spectra as well. Therefore, this was
not the pure product. The final yield of the product was 26.6%.

Figure 7: Proton NMR at 300 MHz of the final product of 5-(dimethylamino)-N-(pyridine-4yl)naphthalene-1-sulfonamide which indicates the target compound is present from the spectra.
However, just as figure 6 shows impurities, the spectra in figure 7 has a couple as well.
The final compound was present in the proton NMR spectra, and its final yield was 35.8%.
Discussion:
The target molecules were successfully synthesized, however the purity was less than the
guidelines for journal publication. These experiments were time consuming and unsuccessful in
obtaining a pure product of the targeted compounds. The experiment following the method and
procedure above was not effective in synthesizing the target molecule quickly, easily, and
affordably. Therefore, a more efficiently way should be utilized in synthesizing the fluorescent
molecules for enzyme assays. In order to accurately provide evidence for this hypothesis, more

data supporting the claim needs to be presented, and because this molecule could not be
synthesized with high purity, there are no results to support the claim that these molecules could
be potential antibiotics. The molecules needed to be synthesized purely in order for it to be tested
through enzyme binding assays. Once data can be collected from this, the compound can be
analyzed on its binding capabilities to IspF and inhibition properties. The impurities that were
produced with the final product would not accurately provide reliable results because it is not its
pure form thus imposing on the binding affinities to the target enzyme. A better method needs to
be discovered in synthesizing these molecules in order to produce the results needed for this
research project.
The compounds that were being created was going to help in the development of easier,
cheaper, and more reliable compounds that could be used instead to inhibit IspF. The first
compound failed due to an accidental discarding of the final product. The second synthesized
molecule had the target compound but an impurity, triethylamine hydrochloride, that could not
be separated even after Biotage Chromatography, extractions using sodium bicarbonate and
brine, and the vacuum pump. The yield of product was low which did not allow for any further
purification techniques. The third reaction used 4-aminopyridine instead of 2-aminopyridine as a
starting reagent and did create the target product using the described method, but due to time
constraints, the binding affinity could not be tested in time for those results to be included. If
more time was available, more conclusive results and data could be provided. A fourth reaction
with 2-aminopyridine as a starting reagent was started but could not be completed using a better
technique of riding the triethylamine hydrochloride due to time constraints, so the project will be
taken over by one of the graduate students in Dr. Hagen’s laboratory.
Conclusion:
In conclusion, the target sulfonamide compound could not be tested for its binding
abilities to IspF through enzyme assays involving fluorescence quenching. Thus, the
sulfonamides were not able to be tested for IspF enzyme inhibition, leading to no supporting data
that these compounds could be potential antibiotics for microbes using the MEP pathway.
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